Zydus Lifesciences’ shares fell 6% to Rs 1,109 after acquiring a 50% stake in Sterling Biotech for Rs 550 crore. Analysts maintain neutral ratings with target prices of Rs 1,020 and Rs 1,210.
New-age tech companies in India, despite grand IPOs, are facing a harsh reality in the stock market. Many, including Paytm and Nykaa, have seen their
Pharma and healthcare mutual funds have yielded impressive returns in 2024. The sector benefited from resilience amidst corrections in other sectors and steady growth in
Advertiser Disclosure
Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.
Disclaimer
It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003